» Articles » PMID: 38795123

Differentiating Lyme Arthritis: a Case-based Review

Overview
Journal Rheumatol Int
Specialty Rheumatology
Date 2024 May 25
PMID 38795123
Authors
Affiliations
Soon will be listed here.
Abstract

The incidence or prevalence of Lyme arthritis (LA) in Denmark is unknown and assumed very low. No published cases of polymerase chain reaction (PCR)-confirmed LA from Denmark exist. Clinically, LA does not differ from other rheumatic oligoarthritic disorders posing a differential diagnostic challenge. To review the incidence and prevalence of LA to our knowledge and to present a case series of PCR-confirmed LA cases from Denmark. We conducted a systematic literature review via MEDLINE and EMBASE to explore incidence and prevalence rates of LA. Additionally, we present six cases of patients diagnosed with LA in Denmark. Our literature review identified 23 studies reporting prevalence or incidence, yet only ten studies provided estimates ranging from 1.1 to 280/100.000 in the general population. Our case series identified six patients with LA from a localized region in Southern Denmark; all confirmed by Borrelia-specific real-time PCR from synovial fluid. The diagnostic delay was up to 38 months. All patients except one had a history of previous tick bites; none had erythema migrans lesions. All presented with recurrent arthritis in the knee joint, and two had arthritis in the wrist. The literature review showed an incidence of LA ranging from 1.1 to 15.8 per 100.000 in Europe. Our case series suggests a potentially higher prevalence of LA in Denmark than previously believed. Lack of tick exposure history, antibody assessments and test of Borrelia burgdorferi sensu lato DNA in synovial fluid might lead to misdiagnosed cases potentially explaining the assumed low incidence of LA in Denmark.

Citing Articles

New BB0108, BB0126, BB0298, BB0323, and BB0689 Chromosomally Encoded Recombinant Proteins of sensu lato for Serodiagnosis of Lyme Disease.

Grazlewska W, Chmielewski T, Fiecek B, Holec-Gasior L Pathogens. 2024; 13(9).

PMID: 39338958 PMC: 11434722. DOI: 10.3390/pathogens13090767.

References
1.
Stanek G, Fingerle V, Hunfeld K, Jaulhac B, Kaiser R, Krause A . Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2010; 17(1):69-79. DOI: 10.1111/j.1469-0691.2010.03175.x. View

2.
Kullberg B, Vrijmoeth H, van de Schoor F, Hovius J . Lyme borreliosis: diagnosis and management. BMJ. 2020; 369:m1041. DOI: 10.1136/bmj.m1041. View

3.
Rizzoli A, Hauffe H, Carpi G, Vourc H G, Neteler M, Rosa R . Lyme borreliosis in Europe. Euro Surveill. 2011; 16(27). View

4.
Marques A, Strle F, Wormser G . Comparison of Lyme Disease in the United States and Europe. Emerg Infect Dis. 2021; 27(8):2017-2024. PMC: 8314816. DOI: 10.3201/eid2708.204763. View

5.
Ocias L, Jensen B, Knudtzen F, Skarphedinsson S, Dessau R . [Clinical manifestations, diagnosis and treatment of Lyme borreliosis]. Ugeskr Laeger. 2017; 179(18). View